DENALI THERAPEUTCS ($DNLI) posted quarterly earnings results for Q2 2026 on Thursday, August 6th. The company reported earnings of -$0.68 per share, missing estimates of -$0.67 by $0.01. The company also reported revenue of $3,600,000, missing estimates of $14,905,392 by $-11,305,392.
You can see Quiver Quantitative's $DNLI stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
DENALI THERAPEUTCS Hedge Fund Activity
We have seen 146 institutional investors add shares of DENALI THERAPEUTCS stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAR1 CAPITAL MANAGEMENT, LLC added 1,819,339 shares (+3490.9%) to their portfolio in Q1 2026, for an estimated $34,931,308
- POINT72 ASSET MANAGEMENT, L.P. removed 1,700,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $32,640,000
- FMR LLC removed 1,521,837 shares (-25.0%) from their portfolio in Q1 2026, for an estimated $29,219,270
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,451,805 shares (-37.1%) from their portfolio in Q1 2026, for an estimated $27,874,656
- VESTAL POINT CAPITAL, LP added 1,308,326 shares (+281.4%) to their portfolio in Q1 2026, for an estimated $25,119,859
- CAPITAL RESEARCH GLOBAL INVESTORS removed 1,214,656 shares (-32.6%) from their portfolio in Q1 2026, for an estimated $23,321,395
- ARTISAN PARTNERS LIMITED PARTNERSHIP added 1,099,719 shares (+inf%) to their portfolio in Q1 2026, for an estimated $21,114,604
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
DENALI THERAPEUTCS Price Targets
Multiple analysts have issued price targets for $DNLI recently. We have seen 8 analysts offer price targets for $DNLI in the last 6 months, with a median target of $37.0.
Here are some recent targets:
- Matthew Harrison from Morgan Stanley set a target price of $35.0 on 05/26/2026
- Thomas Shrader from BTIG set a target price of $39.0 on 05/11/2026
- Laura Chico from Wedbush set a target price of $23.0 on 05/08/2026
- Marc Goodman from Leerink Partners set a target price of $35.0 on 04/22/2026
- Joel Beatty from Baird set a target price of $34.0 on 04/07/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $42.0 on 03/26/2026
- Salveen Richter from Goldman Sachs set a target price of $40.0 on 03/26/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
